Literature DB >> 28199053

The effect of tonsillectomy on the morbidity from recurrent tonsillitis.

C M Douglas1, K Lang1, W M Whitmer2, J A Wilson3, K Mackenzie1.   

Abstract

BACKGROUND: Tonsillitis is a common condition with an incidence in UK general practice of 37 per 1000 population a year.1 Recurrent tonsillitis results in significant morbidity and impacts on individuals' quality of life. This study assesses the morbidity and quality of life of adults with recurrent tonsillitis, and the impact of surgical intervention on their health state.
OBJECTIVES: To describe disease-specific and global quality of life for adults with recurrent tonsillitis 6 months after tonsillectomy, using two instruments: the health impact of throat problems (HITP) and EuroQol-visual analogue scale questionnaire. To assess the overall health benefit from tonsillectomy as an intervention using the Glasgow Benefit Inventory (GBI). To assess potential predictors of tonsillectomy benefit.
DESIGN: A prospective, observational cohort audit of patients who have fulfilled Scottish Intercollegiate Guideline Network (SIGN) criteria for tonsillectomy.2
SETTING: Secondary care, teaching hospital. PARTICIPANTS: Seventy patients (57 female), median age 20 years (range 13-41).
RESULTS: Median preoperative HITP was 47 (range 15-67), compared to 4 (0-72), (P<.001) 6 months following surgery. Median HITP difference was 39.5 (range -20 to 75). There was no significant change in global Quality of Life. Median overall 6 months GBI was 39 (-3 to 100). Patients had an average of 27 episodes of tonsillitis over a period of seven years before "achieving" tonsillectomy, significantly higher than the SIGN guidelines of three or more episodes over three years.
CONCLUSIONS: Recurrent tonsillitis causes a poor disease-specific quality of life. Patients experienced a median of three episodes per year for seven years before tonsillectomy. Following tonsillectomy, patients had a significant improvement in their disease-specific quality of life. Baseline HITP significantly improved after tonsillectomy. The results imply patients with recurrent acute tonsillitis may be experiencing undue delay.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  SIGN guidelines; quality of life; sore throat; tonsillitis

Mesh:

Year:  2017        PMID: 28199053      PMCID: PMC5592091          DOI: 10.1111/coa.12850

Source DB:  PubMed          Journal:  Clin Otolaryngol        ISSN: 1749-4478            Impact factor:   2.597


  22 in total

1.  [Development and validation of the Tonsillectomy Outcome Inventory 14].

Authors:  T Skevas; C Klingmann; P K Plinkert; I Baumann
Journal:  HNO       Date:  2012-09       Impact factor: 1.284

2.  Tonsillectomy under threat: auditing the indications for performing tonsillectomy.

Authors:  S Silva; M Ouda; S Mathanakumara; E Ridyard; P Morar
Journal:  J Laryngol Otol       Date:  2012-06       Impact factor: 1.469

3.  The role of tonsillectomy in the initial diagnostic work-up of head and neck squamous cell carcinoma of unknown primary.

Authors:  E Berta; I Atallah; E Reyt; E Boyer; A Karkas; C-A Righini
Journal:  Eur Ann Otorhinolaryngol Head Neck Dis       Date:  2014-11       Impact factor: 2.080

4.  Scottish Intercollegiate Guidelines Network (SIGN) guidelines on tonsillectomy: a three cycle audit of clinical record keeping and adherence to national guidelines.

Authors:  Alun Williams; Patrick Lee; Alastair Kerr
Journal:  J Laryngol Otol       Date:  2002-06       Impact factor: 1.469

5.  Evaluation of patient benefit from nasal septal surgery for nasal obstruction.

Authors:  Sandeep Uppal; Hiran Mistry; Shri Nadig; Gary Back; Andrew Coatesworth
Journal:  Auris Nasus Larynx       Date:  2005-03-23       Impact factor: 1.863

6.  Efficacy and quality-of-life impact of adult tonsillectomy.

Authors:  N Bhattacharyya; L J Kepnes; J Shapiro
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2001-11

7.  Why has antibiotic prescribing for respiratory illness declined in primary care? A longitudinal study using the General Practice Research Database.

Authors:  Mark Ashworth; Radoslav Latinovic; Judith Charlton; Kate Cox; Gill Rowlands; Martin Gulliford
Journal:  J Public Health (Oxf)       Date:  2004-09       Impact factor: 2.341

8.  Benefit from tonsillectomy in adult patients with chronic tonsillitis.

Authors:  Ingo Baumann; Hanka Kucheida; Gunnar Blumenstock; Ilse M Zalaman; Marcus M Maassen; Peter K Plinkert
Journal:  Eur Arch Otorhinolaryngol       Date:  2006-02-21       Impact factor: 2.503

9.  Quality-of-life effect of tonsillectomy in a young adult group.

Authors:  Amanda L Richards; Michael Bailey; Robin Hooper; Peter Thomson
Journal:  ANZ J Surg       Date:  2007-11       Impact factor: 1.872

10.  The rising rate of admissions for tonsillitis and neck space abscesses in England, 1991-2011.

Authors:  A S Lau; N S Upile; M D Wilkie; S C Leong; A C Swift
Journal:  Ann R Coll Surg Engl       Date:  2014-05       Impact factor: 1.891

View more
  4 in total

1.  [Tonsil surgery in Brandenburg-trends between 2013 and 2017].

Authors:  A M Franzen; M Jungehülsing; U Berthold; J Rudolf; M Herzog; N Heinze; B Didczuneit-Sandhop; J Kanzock; T Schrom
Journal:  HNO       Date:  2019-08       Impact factor: 1.284

Review 2.  Quality of life after tonsillectomy in adult patients with recurrent acute tonsillitis: a systematic review.

Authors:  Hannah Inez Houborg; Tejs Ehlers Klug
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-01-19       Impact factor: 2.503

3.  Normative tonsillectomy outcome inventory 14 values as a decision-making tool for tonsillectomy.

Authors:  Michaela Plath; Matthias Sand; Philippe A Federspil; Peter K Plinkert; Ingo Baumann; Karim Zaoui
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-09-22       Impact factor: 2.503

4.  Increased levels of S100A8/A9, IL-1ß and IL-18 as a novel biomarker for recurrent tonsillitis.

Authors:  Christoph Spiekermann; Alicia Seethaler; Annika McNally; Markus Stenner; Claudia Rudack; Johannes Roth; Thomas Vogl
Journal:  J Inflamm (Lond)       Date:  2021-06-29       Impact factor: 4.981

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.